Mourabit Halima, Author at MediaMedic

Global Quality, Chinese Evidence | Professor Xinhong Wu: Dual Approval of Lerociclib Marks a New Era of Optimized CDK4/6 Inhibitor Therapy

By Mourabit Halima 2025.11.01

Editor’s Note: The China National Medical Products Administration (NMPA) has officially approved the novel CDK4/6 inhibitor (CDK4/6i) Lerociclib for two indications in adult patients with hormone receptor–positive, HER2–negative (HR+/HER2-) locally…

Global Quality, Chinese Evidence: Lerociclib Approved in China for HR+ Advanced Breast Cancer

By Mourabit Halima 2025.11.01

Introduction CDK4/6 inhibitors (CDK4/6i) have become the cornerstone of standard therapy for patients with HR+/HER2- advanced breast cancer. However, differences in efficacy and safety profiles exist among currently approved CDK4/6…

Global Quality, Chinese Evidence | Professor Yueyin Pan: Lerociclib Officially Approved in China — A Powerful New Option for HR+/HER2- Breast Cancer

By Mourabit Halima 2025.11.01

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) have dramatically improved outcomes for patients with hormone receptor–positive, HER2–negative (HR+/HER2-) advanced breast cancer, yet differences remain among available agents in terms of efficacy, safety,…

Breaking News｜Lerociclib (Rujianing®) Begins Clinical Use, Redefining HR+ Breast Cancer Care in China

By Mourabit Halima 2025.11.01

Editor’s Note: Breast cancer remains the most common malignancy among women, with hormone receptor–positive/HER2-negative (HR+/HER2–) cases accounting for approximately 70% of all diagnoses. For patients with advanced disease, first-line therapy…

Professor Cao Xingyu: Clinical Management and Transplant Strategies in Mycosis Fungoides and Sézary Syndrome | 13th Ludaopei Hematology Conference

By Mourabit Halima 2025.11.01

On August 22–23, 2025, the 13th Ludaopei Hematology Conference was held in Beijing, jointly organized by the Beijing Health Promotion Association and the Guangzhou Kapok Oncology and Rare Disease Foundation,…

FACO 2025 Highlights | Advances in Biliary Tract Cancer Treatment

By Mourabit Halima 2025.10.31

Professor Jin Li & Professor Joon Oh Park: Carrying the Torch Forward with Unity and Collaboration — FACO as a Platform for Advancing Comprehensive Academic Cooperation and the Joint Progress of Asian Clinical Oncology

By Mourabit Halima 2025.10.29

Editor’s Note: The 13th Federation of Asian Clinical Oncology (FACO) Annual Meeting was grandly held in Shanghai on October 24–25, 2025. As a collaborative organization jointly initiated by the…

ISEH 2025 | Harvesting the Fruits of Collaboration: China–Japan Symposium on Stem Cells and Cell Therapy Opens a New Chapter

By Mourabit Halima 2025.10.28

Editor’s Note: As autumn scents the air with osmanthus blossoms, leading scientists gathered in Kumamoto for an intellectual feast. The 54th Annual Scientific Meeting of the International Society for Experimental…

ESMO Global Insight | Professor Andrea Necchi: Disitamab Vedotin Plus Immunotherapy Nearly Doubles Overall Survival in Advanced HER2-Expressing Urothelial Carcinoma

By Mourabit Halima 2025.10.28

The combination of antibody–drug conjugates (ADCs) with immunotherapy has delivered major breakthroughs across several tumor types, including urothelial carcinoma. At the 2025 European Society for Medical Oncology (ESMO) Congress, results from a pivotal Phase III trial (LBA7) were presented showing that the HER2-targeted ADC disitamab vedotin, combined with the PD-1 inhibitor toripalimab, nearly doubled overall survival compared with chemotherapy as first-line treatment for patients with HER2-expressing locally advanced or metastatic urothelial carcinoma (la/mUC). This novel regimen, centered on an innovative ADC, may redefine first-line therapy—though several key questions remain.

Highlights from the 13th International Conference of the Federation of Asian Clinical Oncology (FACO 2025)

By Mourabit Halima 2025.10.25

At the recent FACO 2025 Conference held in Shanghai, Dr. Joon Oh Park, President of KSMO and President-elect of FACO, shared his perspectives on the evolving landscape of cancer treatment…